(Q57702684)

1

0 references

D. Corna

2

0 references

D. Rottoli

3

0 references

C. Zanchi

4

0 references

M. Abbate

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001528

5

0 references

language of work or name

English

0 references

publication date

July 2006

0 references

published in

Kidney International

0 references

volume

70

0 references

issue

1

0 references

page(s)

97-103

0 references

exact match

0 references

cites work

Recent advances in the pathogenesis of lupus nephritis: autoantibodies and B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Immunopathogenesis of lupus and lupus nephritis: recent insights

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Immunosuppressive drug therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Novel therapies in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Role of platelet-derived growth factor in renal injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Mechanism of action and in vivo role of platelet-derived growth factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Renal platelet-derived growth factor gene expression in NZB/W F1 mice with lupus and ddY mice with IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Calorie restriction decreases platelet-derived growth factor (PDGF)-A and thrombin receptor mRNA expression in autoimmune murine lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Expression of platelet-derived growth factor in lupus nephritis in MRL/MpJ-1pr/1pr mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Gene expression of PDGF and PDGF receptor in various forms of glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Independent regulation of transforming growth factor-beta1 transcription and translation by glucose and platelet-derived growth factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001528

7 January 2021